Indication
Small cell lung carcinoma
Small cell lung carcinoma is an aggressive, high-grade neuroendocrine malignancy that originates primarily in the respiratory epithelium of the bronchial tree. Read more about Small cell lung carcinoma
87 drugs 49 manufacturers
Drugs that treat it
Common Small cell lung carcinoma therapies.
ETOPOPHOS (etoposide phosphate)
CISPLATIN
ZEPZELCA (lurbinectedin)
ADRIAMYCIN (doxorubicin HCl)
HYCAMTIN (topotecan HCl)
HYCAMTIN (topotecan HCl)
KEMOPLAT (cisplatin)
DOXORUBICIN HCL
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonSmall cell lung carcinoma is an aggressive, high-grade neuroendocrine malignancy that originates primarily in the respiratory epithelium of the bronchial tree.
It predominantly affects adults with a heavy history of tobacco exposure, accounting for approximately 15% of all pulmonary malignancies.
Pathophysiologically, it is defined by near-universal functional inactivation of tumor suppressor genes TP53 and RB1, rapid tumor doubling time, high mitotic activity, and widespread neuroendocrine differentiation.
Histologically and clinically, it is characterized by sheets of small, poorly differentiated cells with scant cytoplasm, granular nuclear chromatin, extensive necrosis, and a marked propensity for early hematogenous dissemination and paraneoplastic manifestations.
- nih.gov
Small cell lung carcinoma is an aggressive, high-grade neuroendocrine malignancy that originates primarily in the respiratory epithelium of the bronchial tree Histologically and clinically, it is characterized by sheets of small, poorly differentiated cells with scant cytoplasm, granular nuclear chromatin, extensive necrosis, and a marked propensity for early hematogenous dissemination and paraneoplastic manifestations
- mypathologyreport.ca
Small cell lung carcinoma is an aggressive, high-grade neuroendocrine malignancy that originates primarily in the respiratory epithelium of the bronchial tree
- nih.gov
It predominantly affects adults with a heavy history of tobacco exposure, accounting for approximately 15% of all pulmonary malignancies Pathophysiologically, it is defined by near-universal functional inactivation of tumor suppressor genes TP53 and RB1, rapid tumor doubling time, high mitotic activity, and widespread neuroendocrine differentiation Histologically and clinically, it is characterized by sheets of small, poorly differentiated cells with scant cytoplasm, granular nuclear chromatin, ...
- researchgate.net
It predominantly affects adults with a heavy history of tobacco exposure, accounting for approximately 15% of all pulmonary malignancies Pathophysiologically, it is defined by near-universal functional inactivation of tumor suppressor genes TP53 and RB1, rapid tumor doubling time, high mitotic activity, and widespread neuroendocrine differentiation
- webpathology.com
Pathophysiologically, it is defined by near-universal functional inactivation of tumor suppressor genes TP53 and RB1, rapid tumor doubling time, high mitotic activity, and widespread neuroendocrine differentiation Histologically and clinically, it is characterized by sheets of small, poorly differentiated cells with scant cytoplasm, granular nuclear chromatin, extensive necrosis, and a marked propensity for early hematogenous dissemination and paraneoplastic manifestations
- youtube.com
Histologically and clinically, it is characterized by sheets of small, poorly differentiated cells with scant cytoplasm, granular nuclear chromatin, extensive necrosis, and a marked propensity for early hematogenous dissemination and paraneoplastic manifestations
Personalize your experience
Follow Small cell lung carcinoma and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.